Spine implant safety under the microscope: 1,050 patients enrolled
NCT ID NCT04418830
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 1,050 adults who are getting NuVasive interbody implants during spine surgery for conditions like degenerative disc disease or spinal stenosis. Researchers are monitoring complications, bone fusion, and patient-reported pain relief over 24 months. The goal is to better understand the implants' safety and long-term performance.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NuVasive interbody implants (medical device)
- What this could lead to
- If successful, this study could confirm that these implants are safe and effective for treating degenerative spine conditions, helping guide future surgical decisions.
- What could go wrong
- This is an observational study, not a randomized trial, so results may not prove superiority over other treatments. Complications like implant failure or non-fusion are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,050 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2020
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The Enrolled Population will include all subjects who meet the criteria for enrollment, specifically, those subjects who: * Satisfied the inclusion and exclusion criteria * Signed the informed consent * Underwent the surgical procedure, as defined in this protocol Subjects not meeting any of these criteria will not be considered enrolled in the study, and therefore not included in any study population or analysis.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients who are ≥18 years of age at the time of consent 2. Planned spine surgery using interbody implants at: 1. One or two adjacent thoracic, lumbar, and/or lumbosacral levels for degenerative disc disease or degenerative spondylolisthesis, or 2. One or two adjacent thoracic, lumbar, and/or lumbosacral levels for spinal stenosis (not applicable for MLX, TLX, or XLX ACR), or 3. Any number of thoracic, lumbar, and/or lumbosacral levels for degenerative scoliosis (defined as \>10º coronal curve), or 4. Any number of thoracic, lumbar, and/or lumbosacral levels for sagittal deformity (not applicable for MLX, TLX, or XLX ACR). 3. Use of one of the following implants (NuVasive, Inc., San Diego, CA): 1. Base Interfixated 2. Brigade Interfixated 3. Coalesce Thoracolumbar 4. Cohere TLIF 5. Cohere XLIF 6. Coroent Ti PLIF 7. Coroent Ti TLIF 8. Coroent Ti XLIF 9. MLX 10. Modulus ALIF 11. Modulus TLIF 12. Modulus XLIF 13. TLX 14. XLX ACR 4. Interbody fusion with one or more of the following (as allowed by implant type): 1. autograft 2. allograft (i.e., cancellous and/or corticocancellous allograft bone) 3. Attrax Putty (NuVasive) (not applicable for MLX, TLX, or XLX ACR) 5. NuVasive supplemental internal fixation cleared by the applicable regulatory body for use in the thoracolumbar spine (unless the interbody device to be used is interfixated and is cleared by the regulatory body to be used standalone) 6. Able to undergo surgery based on physical exam, medical history, and surgeon judgment 7. Understands the conditions of enrollment, is willing to follow medical advice including postoperative activity restrictions per the surgeon's standard of care, and is willing to sign an informed consent form to participate in the study Exclusion Criteria: 1. Use of any bone graft that is not cleared by the applicable regulatory body for use within interbody implants. Examples of these include: 1. Bone morphogenetic protein (BMP) (e.g., Infuse (Medtronic)) 2. Synthetic bone graft extenders (e.g., Attrax Scaffold (NuVasive), Formagraft (NuVasive), Mastergraft (Medtronic), Vitoss (Stryker), Actifuse (Baxter), nanOss (RTI Surgical), Fibergraft (Prosidyan/Depuy Synthes), ChronOs (Depuy Synthes)) 3. Demineralized bone matrices (DBM) regulated as medical devices by the FDA (e.g., Grafton Putty/Gel (Medtronic), DBX (MTF/Depuy Synthes), Accell Evo3 (IsoTis), Propel Putty/Gel (NuVasive)) 4. Peptide enhanced bone graft (e.g., iFactor (Cerapedics)) 2. Previous lumbar fusion surgery at the level(s) to be treated (adjacent level surgery is acceptable; prior decompression is acceptable) 3. Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested) 4. Use of bone growth stimulators postoperatively 5. Active smoking within 6 weeks before surgery 6. Patient has known sensitivity to the materials implanted 7. Systemic or local infection (latent or active) or signs of local inflammation 8. Patient has inadequate bone stock or bone quality, or a physical or medical condition that would prohibit beneficial surgical outcomes based on surgeon judgment 9. Patient is a prisoner 10. Patient is participating in another clinical study that would confound study data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Degenerative disc disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
16 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Atlantic Brain and Spine
Wilmington, North Carolina, 28401, United States
-
Beaumont Hospital Research Institute
Royal Oak, Michigan, 48073, United States
-
Columbia Orthopaedics Group
Columbia, Missouri, 65201, United States
-
DuPage Medical Group
Naperville, Illinois, 60540, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Hartford Healthcare Bone and Joint Institute
Hartford, Connecticut, 06106, United States
-
Hoag Orthopedics
Orange, California, 92868, United States
-
Lyerly Neurosurgery
Jacksonville, Florida, 32207, United States
-
Northwestern University
Chicago, Illinois, 60610, United States
-
Ohio State University
Dublin, Ohio, 43016, United States
-
Summa Health
Akron, Ohio, 44320, United States
-
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213, United States
-
University of California San Diego
La Jolla, California, 92037, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Valley Spine Care
Merced, California, 95348, United States
-
Verma Spine
Los Alamitos, California, 90720, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can keyhole spine fusion ease chronic back pain?
- Can ultrasound dye reveal spinal cord damage Mid-Surgery?
- A conversation before spine surgery could change how patients recover
- Can a new bone graft match the gold standard for spinal fusion?
- Can a nanotube surface help spinal bones fuse faster?
- Can a growth factor from donor bone improve spinal fusion?